BEYOND FACTOR

Serial Number 87435526
606

Registration Progress

Application Filed
May 3, 2017
Under Examination
May 8, 2018
Approved for Publication
Mar 13, 2018
Published for Opposition
Mar 13, 2018
Registered

Basic Information

Serial Number
87435526
Filing Date
May 3, 2017
Published for Opposition
March 13, 2018
Abandonment Date
December 10, 2018
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Dec 10, 2018
Classes
042

Rights Holder

Alnylam Pharmaceuticals, Inc.

03
Address
300 Third Street, 3rd Floor
Cambridge, MA 02142

Ownership History

Alnylam Pharmaceuticals, Inc.

Original Applicant
03
Cambridge, MA

Alnylam Pharmaceuticals, Inc.

Owner at Publication
03
Cambridge, MA

Legal Representation

Attorney
Ann Lamport Hammitte

USPTO Deadlines

All Deadlines Cleared

All 5 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

16 events
Date Code Type Description
Dec 10, 2018 ABN6 S ABANDONMENT - NO USE STATEMENT FILED
Dec 10, 2018 MAB6 E ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
May 8, 2018 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 13, 2018 PUBO A PUBLISHED FOR OPPOSITION
Mar 13, 2018 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 21, 2018 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 31, 2018 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 31, 2018 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 30, 2018 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 30, 2018 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 3, 2017 CNRT R NON-FINAL ACTION WRITTEN
Aug 3, 2017 GNRT F NON-FINAL ACTION E-MAILED
Aug 3, 2017 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 31, 2017 DOCK D ASSIGNED TO EXAMINER
May 9, 2017 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 6, 2017 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 042
Scientific research, scientific research for others in the treatment of hemophilia; consulting services in the field of researching and development of pharmaceutical preparations for the treatment of hemophilia
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
042